Abstracts from 2014 through the most recent CROI can be viewed in this searchable database once they have been presented at the conference. Abstract Contents: The searchable database includes abstract text as submitted by the authors prior to CROI. Study data might be updated during the presentation at CROI. Please refer to the electronic poster or webcast for updates. Searching the Abstract Database: Enter the criteria below and click the “Search” button. After the search has been entered, the results will appear below the search form.

CROI conference materials (eg, the conference program, Abstract eBook, electronic posters, CROI logo, etc) are protected by copyright. Permission to replicate or reproduce these elements, in whole or in part, must be obtained from the CROI Conference Manager, the International Antiviral Society-USA (IAS-USA). Study data (including figures within abstracts or electronic posters) are the property of the study authors. Permission to use data and figures cannot be given by IAS–USA unless it is for regulatory reasons. For more information, please email CROIabstracts@iasusa.org.

Search Results

1277 Results

727 – Modifying PF74 Improves Anti-HIV-1 Activity Against the Resistance-Associated Capsid Mutation N74D

Background Lenacapavir (LEN) is an FDA-approved drug for highly treatment-experienced individuals living with multidrug-resistant HIV-1 infection. LEN inhibits HIV-1 replication with sub-nanomolar potency by targeting the capsid protein (CA) at the “FG-binding pocket” (FGBP). Clinical trials report the emergence of CA mutations like M66I and N74D after LEN treatment. N74D is also selected by PF74,…

737 – Virologic Success on InSTI-Based ART Despite Archived InSTI DRMs

Background The relevance of drug resistance mutation (DRM) detection in HIV-1 proviral sequencing for the prediction of virological success on antiretroviral therapy (ART) remains unclear. In this retrospective study, we examined archived INSTI DRMs in people with HIV (PWH) virologically suppressed on INSTI-based regimens. Methods PWH with at least one HIV-1 integrase proviral sequencing were…

747 – Predictors of HIV Drug Resistance to Dolutegravir in 4 PEPFAR-Supported Countries

Background Dolutegravir-based regimens (DBR) represent >92% of drugs dispensed in PEPFAR-supported programs. Monitoring emergence of and characterizing the risk factors for dolutegravir (DTG) drug resistance (DR) acquisition is a key priority to ensure the continued efficacy and durability of these regimens. We report risk factors for DTG DR identified in a large cohort of patients…

725 – Effect of SNG001, Inhaled IFN-β1a, on SARS-CoV-2 Diversity and Evolution

Background Interferon resistance has been implicated in SARS-CoV-2 escape from innate immune responses, but interferon’s specific impact on viral evolution is unknown. SNG001 is an inhaled interferon-β1a treatment for COVID-19 which was evaluated in the ACTIV-2/A5401 randomized placebo-controlled trial. Although SNG001 did not accelerate viral decay, there was a trend towards fewer hospitalizations in the…

734 – No Virologic Failure in Patients Switched to Doravirine Treatment With Past Resistance Mutations

Background Doravirine (DOR) is licensed in patients living with HIV (PWH) harboring no prior resistance to any NNRTIs. We aimed to evaluate in real life the efficacy of DOR-containing regimen in PWH with prior NNRTIs virological failure and selected NNRTI resistance-associated mutations (RAMs). Methods This observational single center study included all PWH who have switched…

722 – Structural and Mechanistic Insights Into Cabotegravir Resistance in HIV-1 Integrase

Background HIV-1 infection requires the integration of viral DNA into host chromatin, a process mediated by the viral enzyme integrase (IN). This step is effectively blocked by IN strand transfer inhibitors (INSTIs), a key class of antiretroviral drugs. However, resistance to even the most potent INSTIs is becoming more of a clinical problem and the…

723 – The Barrier to Escape From Broadly Neutralizing Antibodies Varies Between Different HIV-1 Isolates

Background Broadly neutralizing antibodies (bNAbs) against HIV-1 have re-invigorated research into antibody therapies and vaccination strategies for prevention, treatment, and cure of HIV-1 because of their unique ability to neutralize diverse HIV-1 strains. While many HIV-1 isolates are initially susceptible to bNAbs, their ability to acquire resistance is unknown. Understanding the evolutionary barriers to bNAb…

729 – High Prevalence of Baseline NRTI Resistance in PWH Switched From Second-Line PI/r to B/F/TAF

Background Patients on PI/r-based regimens in resource-limited settings have high rates of NRTI resistance, but testing is rarely available.  Methods In this open-label prospective trial conducted at GHESKIO in Haiti, virologically suppressed adults on second-line PI/r-based ART were randomized to continue current regimen vs. switch to B/F/TAF. The primary endpoint was the proportion with HIV-1…

735 – HIV-1 Resistance Analysis of Treatment-Naive People With HIV and HBV Receiving B/F/TAF or DTG+F/TDF

Background In the ALLIANCE study (GS-US-380-4458; NCT03547908), bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) was noninferior to dolutegravir + emtricitabine/tenofovir disoproxil fumarate (DTG+F/TDF) at achieving HIV-1 RNA suppression at Week (W) 48 in treatment-naïve adults with HIV-1/hepatitis B virus (HBV) coinfection, with high rates of suppression maintained through End of Study (EoS). We present HIV-1 resistance analyses through EoS for the B/F/TAF…

721 – The Genetic Barrier to Resistance to LEN Is Not Affected by Non-B Subtypes or Treatment Exposure

Background Lenacapavir (LEN) is a HIV-1 capsid inhibitor approved for heavily-treatment experienced (HTE) people with HIV (PWH). This in vitro study aimed to evaluate LEN susceptibility and genetic barrier in B and non-B subtypes derived from therapy naïve (TN) and HTE PWH. Methods Thirty-one NL4-3 based recombinant viruses harbouring clinically derived GAG-PR region were generated…